Stock Market Reviews

Read and share opinions on LIXT (Lixte Biotechnology Holdings, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the st

Latest News

• LIXTE Biotechnology Holdings to Present at the Spartan Capital Investor Conference 2025, November 3
  Oct 29, 2025
• LIXTE Biotechnology Holdings Highlights Q4 2025 Priorities, Including Ongoing Advancement of Lead Candidate LB-100, Strategic Oncology Business Development and Acquisition Plans
  Oct 16, 2025
• LIXTE Bio's Transformational Summer Marked by Leadership Updates, Scientific Progress, and Digital Treasury Strategy (NASDAQ:LIXT)
  Sep 15, 2025
• LIXTE Biotechnology Holdings Makes $2.6 Million Initial Purchase of Digital Currency to Diversify Treasury and for Potential Acquisitions
  Sep 10, 2025
• 24/7 Market News: LIXTE Holds the World's Only Clinical-Stage PP2A Inhibitor
  Sep 5, 2025
• LIXTE Biotechnology Holdings Appoints Two New Board Members and New Chief Financial Officer
  Sep 3, 2025
• 24/7 Market News: LIXTE Showcases LB-100 at First Global Conference on Oncogenic Signaling Activation as Cancer Therapy
  Aug 27, 2025
• 24/7 Market News: LIXTE Targets Large, Unmet Oncology Markets
  Aug 25, 2025
• 24/7 Market News: LIXTE Biotechnology Spotlight- Revisiting the “Too Much of a Good Thing” Strategy for LB-100
  Aug 19, 2025
• LIXTE Biotechnology Holdings Provides Corporate Update
  Aug 18, 2025
• 24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B/2 Trial Readout Expected in 2H 2025
  Aug 15, 2025
• 24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with Multiple Phase 1B/2 Trial Readouts Expected in 2H 2025
  Aug 14, 2025
• LIXTE Biotechnology Holdings Regains Compliance with Nasdaq’s Continued Listing Requirements
  Jul 16, 2025
• Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.’s $1.5 Million Registered Direct Offering
  Jul 9, 2025
• New Clinical Findings Published in Scientific Journal Nature Validate LIXTE’s Ongoing Ovarian and Colorectal Cancer Trials
  Jul 9, 2025
• Lixte Biotechnology Holdings, Inc. Announces the Closing of $1.5 Million Registered Direct Offering
  Jul 8, 2025
• Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.’s $5.0 Million Private Placement
  Jul 8, 2025
• Lixte Biotechnology Holdings, Inc. Announces the Closing of $5.0 Million Private Placement Priced at the Market
  Jul 2, 2025
• Lixte Biotechnology Holdings, Inc. Announces $5.0 Million Private Placement Priced at the Market
  Jul 1, 2025